Skip to main content
Fig. 5 | Respiratory Research

Fig. 5

From: Serum C-C motif chemokine ligand 17 as a predictive biomarker for the progression of non-idiopathic pulmonary fibrosis interstitial lung disease

Fig. 5

Reproduction of the utility of serum CCL17 levels for predicting non-IPF-ILD progression in the validation cohort. (A) Kaplan–Meier curves estimating the probability of overall survival stratified by the serum levels of CCL17 (n = 154). (B) Relative change of %FVC at 1 year in groups with high (n = 68) and low CCL17 levels (n = 86). (C) Receiver operating characteristic curves for evaluating serum CCL17 and ILD-GAP index as predicting composite outcome (relative decline in %FVC ≥ 10%, acute exacerbation, or death) within a year in 67 ILD cases with complete data. (D) Serum CCL17 levels of patients with (n = 12) and without ILD progression within 1 year (n = 70). (E) Percentages of patients with ILD progression within 1 year in groups with high and low CCL17 levels. CCL, C-C motif chemokine ligand; %FVC, percent predicted forced vital capacity; GAP, gender age physiology; HR, hazard ratio; ILD, interstitial lung disease

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us